Demographics, treatment patterns, safety, and real-world effectiveness in patients aged 70 years and over with chronic lymphocytic leukemia receiving bendamustine with or without rituximab: A retrospective study

Therapeutic Advances in Hematology

Volumn 4, Issue 3, 2013, Pages 157-171

  Kolibaba, Kathryn S ^a   Sterchele, James A ^b   Beygi, Hooman ^b   Joshi, Avani D ^c   Forsyth, Michael ^d   Alwon, Erin ^e   Kennealey, Gerard T ^b  

^a Vancouver Cancer Center   (United States)

^b Teva Global Branded Products R and D   (United States)

^c ABBOTT LABORATORIES   (United States)

^d US Oncology   (United States)

^e McKesson   (United States)

Author keywords

bendamustine; chart review; chemoimmunotherapy; chronic lymphocytic leukemia; retrospective; rituximab

Indexed keywords

ANTIBIOTIC AGENT; ANTIEMETIC AGENT; BENDAMUSTINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB;

ABDOMINAL PAIN; AGED; ANTIBIOTIC THERAPY; ARTICLE; BIBLIOGRAPHIC DATABASE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER PATIENT; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; FATIGUE; FEMALE; FEVER; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION; LEUKEMIA RELAPSE; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OUTPATIENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SEPSIS; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; WEIGHT REDUCTION;

EID: 84993683967     PISSN: 20406207     EISSN: 20406215     Source Type: Journal    
DOI: 10.1177/2040620713478629     Document Type: Article

References (29)

1. Aivado M. Schulte K. Henze L. Burger J. Finke J. Haas R. (2002) Bendamustine in the treatment of chronic lymphocytic leukemia: results and future perspectives. Semin Oncol 29(4 Suppl. 13): 19–22.
2. Badoux X. Keating M. Wang X. O'Brien S. Ferrajoli A. Faderl S. et al. (2011) Fludarabine, cyclophosphamide and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood 117: 3016–3024.
3. Bergmann M. Goebeler M. Herold M. Emmerich B. Wilhelm M. Ruelfs C. et al. (2005) Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I / II study of the German CLL Study Group. Haematologica 90: 1357–1364.
4. Cheson B. Bennett J. Grever M. Kay N. Keating M. O'Brien S. et al. (1996) National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 87: 4990–4997.
5. Cheson B. Rummel M. (2009) Bendamustine: rebirth of an old drug. J Clin Oncol 27: 1492–1501.
6. Cheson B. Wendtner C. Pieper A. Dreyling M. Friedberg J. Hoelzer D. et al. (2010) Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel. Clin Lymphoma Myeloma Leuk 10: 21–27.
7. Dreger P. Döhner H. Ritgen M. Böttcher S. Busch R. Dietrich S. et al. (2010) Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood 116: 2438–2447.
8. Fischer K. Cramer P. Busch R. Böttcher S. Bahlo J. Schubert J. et al. (2012) Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 30: 3209–3216.
9. Fischer K. Cramer P. Busch R. Stilgenbauer S. Bahlo J. Schweighofer C. et al. (2011) Bendamustine combined with rituximab in patients with relapsed and / or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 29: 3559–3566.
10. Foon K. Hallek M. (2010) Changing paradigms in the treatment of chronic lymphocytic leukemia. Leukemia 24: 500–511.
11. Gribben J. (2010) How I treat CLL up front. Blood 115: 187–197.
12. Gribben J. Zahrieh D. Stephans K. Bartlett-Pandite L. Alyea E. Fisher D. et al. (2005) Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood 106: 4389–4396.
13. Hallek M. (2009) State-of-the-art treatment of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 440–449.
14. Hallek M. Cheson B. Catovsky D. Caligaris-Cappio F. Dighiero G. Döhner H. et al. (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111: 5446–5456.
15. Hallek M. Fischer K. Fingerle-Rowson G. Fink A. Busch R. Mayer J. et al. (2010) Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 376: 1164–1174.
16. Horn J. Kleber M. Hieke S. Schmitt-Gräff A. Wäsch R. Engelhardt M. (2012) Treatment option of bendamustine in combination with rituximab in elderly and frail patients with aggressive B-non-Hodgkin lymphoma: rational, efficacy, and tolerance. Ann Hematol 91: 1579–1586.
17. Jemal A. Siegel R. Xu J. Ward E. (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277–300.
18. Kath R. Blumenstengel K. Fricke H. Höffken K. (2001) Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia. J Cancer Res Clin Oncol 127: 48–54.
19. Kim Y. Jung Y. Chen J. Alhasan A. Kaewsaard P. Zhang Y. et al. (2010) Evidences showing wide presence of small genomic aberrations in chronic lymphocytic leukemia. BMC Res Notes 3: 341.
20. Knauf W. Lissitchkov T. Aldaoud A. Liberati A. Loscertales J. Herbrecht R. et al. (2009) Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 27: 4378–4384.
21. Leoni L. Bailey B. Reifert J. Bendall H. Zeller R. Corbeil J. et al. (2008) Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 14: 309–317.
22. Lissitchkov T. Arnaudov G. Peytchev D. Merkle K. (2006) Phase-I/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pre-treated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy. J Cancer Res Clin Oncol 132: 99–104.
23. NCCN (National Comprehensive Cancer Network) (2012) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™): Non-Hodgkin's Lymphomas. Version 3.2012. Available at: http://www.nccn.org/professionals/physician_gls/pdf/nhl.pdf (accessed 4 December 2012).
24. Robak T. Dmoszynska A. Solal-Céligny P. Warzocha K. Loscertales J. Catalano J. et al. (2010 a) Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 10: 1756–1765.
25. Robak T. Lech-Maranda E. Robak P. (2010 b) Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia. Expert Rev Anticancer Ther 10: 1529–1543.
26. Rummel M. Chow K. Hoelzer D. Mitrou P. Weidmann E. (2002) In vitro studies with bendamustine: enhanced activity in combination with rituximab. Semin Oncol 29(4 Suppl. 13): 12–14.
27. Tageja N. Nagi J. (2010) Bendamustine: something old, something new. Cancer Chemother Pharmacol 66: 413–423.
28. Tam C. O'Brien S. Wierda W. Kantarjian H. Wen S. Do K. et al. (2008) Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 112: 975–980.
29. Wierda W. Keating M. O'Brien S. (2008) Chronic lymphocytic leukemias. In Ed. de Vita V. Jr Lawrence T. Rosenberg S. (eds), De Vita, Hellman, and Rosenberg's Cancer Principles & Practice of Oncology, 8th ed., vol. 2. Philadelphia: Lippincott Williams & Wilkins, pp. 2278–2292.